Keeping Track: New Claims For Tukysa, Brukinsa; US FDA Wants More Patients To Support Donanemab, Pediatric Airsupra Bids

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Keeping Track Feature image

Alzheimer’s disease continues to provide the big drug development story for the new year thanks to Eli Lilly and Company’s announcement of a complete response letter for donanemab less than two weeks after the FDA approved Eisai Co., Ltd./Biogen, Inc.’s Leqembi (lecanemab-irmb), but oncology is holding up its end with the recent approvals of supplemental indications for two targeted therapies, Seagen Inc.’s Tukysa (tucatinib) and BeiGene, Ltd.’s Brukinsa (zanubrutinib).

The Center for Biologics Evaluation and Research contributed a new claim for maternal use of Sanofi’s Adacel vaccine to...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers